155 related articles for article (PubMed ID: 35500150)
41. Aberrant blood MALT1 and its relevance with multiple organic dysfunctions, T helper cells, inflammation, and mortality risk of sepsis patients.
Wang Y; Huang Q; He F
J Clin Lab Anal; 2022 Apr; 36(4):e24331. PubMed ID: 35262976
[TBL] [Abstract][Full Text] [Related]
42. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 exaggerates multiple organ injury, inflammation, and immune cell imbalance by activating the NF-κB pathway in sepsis.
Wang Y; Liu Z; Zhang M; Yu B; Ai F
Front Microbiol; 2023; 14():1117285. PubMed ID: 36960276
[TBL] [Abstract][Full Text] [Related]
43. Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1/2/17 cells, and clinical response of tumor necrosis factor inhibitor.
Deng J; Jiang Y; Luan L; Fu S; Huang M; Dai Z; Liao Y; Guo S; Fu Y
Ir J Med Sci; 2024 Feb; 193(1):165-172. PubMed ID: 37420045
[TBL] [Abstract][Full Text] [Related]
44. Refining the dermatological spectrum in primary immunodeficiency: mucosa-associated lymphoid tissue lymphoma translocation protein 1 deficiency mimicking Netherton/Omenn syndromes.
Wiegmann H; Reunert J; Metze D; Marquardt T; Engel T; Kunde V; Ehl S; Foell D; van den Heuvel I; Oji V; Wittkowski H
Br J Dermatol; 2020 Jan; 182(1):202-207. PubMed ID: 31049936
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of add-on tacrolimus on methotrexate to maintain clinical remission after rediscontinuation of a tumor necrosis factor inhibitor in rheumatoid arthritis patients who relapsed shortly after discontinuation of the same tumor necrosis factor inhibitor due to clinical remission.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2017 Jan; 27(1):29-34. PubMed ID: 27143107
[TBL] [Abstract][Full Text] [Related]
46. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
[TBL] [Abstract][Full Text] [Related]
47. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
[TBL] [Abstract][Full Text] [Related]
48. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
49. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial.
Wientjes MHM; Atiqi S; Wolbink GJ; Nurmohamed MT; Boers M; Rispens T; de Vries A; van Vollenhoven RF; van den Bemt BJF; den Broeder AA
Trials; 2021 Jun; 22(1):406. PubMed ID: 34147123
[TBL] [Abstract][Full Text] [Related]
50. Deletion of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 in Mouse T Cells Protects Against Development of Autoimmune Arthritis but Leads to Spontaneous Osteoporosis.
Gilis E; Gaublomme D; Staal J; Venken K; Dhaenens M; Lambrecht S; Coudenys J; Decruy T; Schryvers N; Driege Y; Dumas E; Demeyer A; De Muynck A; van Hengel J; Van Hoorebeke L; Deforce D; Beyaert R; Elewaut D
Arthritis Rheumatol; 2019 Dec; 71(12):2005-2015. PubMed ID: 31259485
[TBL] [Abstract][Full Text] [Related]
51. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
[TBL] [Abstract][Full Text] [Related]
53. Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.
Yu Z; Gao L; Zang Y; Cheng L; Gao W; Xu Y
Immun Inflamm Dis; 2024 Feb; 12(2):e1166. PubMed ID: 38415932
[TBL] [Abstract][Full Text] [Related]
54. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
55. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A
Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698
[TBL] [Abstract][Full Text] [Related]
56. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors.
Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO
Autoimmun Rev; 2020 May; 19(5):102509. PubMed ID: 32173513
[TBL] [Abstract][Full Text] [Related]
57. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
Raaschou P; Frisell T; Askling J;
Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
[TBL] [Abstract][Full Text] [Related]
58. MALT1 positively correlates with Th1 cells, Th17 cells, and their secreted cytokines and also relates to disease risk, severity, and prognosis of acute ischemic stroke.
Chen X; Zhang X; Lan L; Xu G; Li Y; Huang S
J Clin Lab Anal; 2021 Sep; 35(9):e23903. PubMed ID: 34273195
[TBL] [Abstract][Full Text] [Related]
59. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
60. The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors.
Biggioggero M; Mesina F; Favalli EG
Biomed Res Int; 2019; 2019():6107217. PubMed ID: 30733963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
